{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:41:35Z","timestamp":1790106095363,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.kint.2017.12.011","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T09:34:59Z","timestamp":1520501699000},"page":"1397-1408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease"],"prefix":"10.1016","volume":"93","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Letierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2017.12.011_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jacc.2008.03.025","article-title":"Managing dyslipidemia in chronic kidney disease","volume":"51","author":"Harper","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2017.12.011_bib2","first-page":"3(3)","article-title":"Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease: summary of recommendation statements and clinical approach to the patient","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2017.12.011_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.12.011_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.03.007","article-title":"Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy\u2013a meta-analysis of 11 randomized controlled trials involving 21,295 participants","volume":"72","author":"Barylski","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kint.2017.12.011_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-016-0550-5","article-title":"Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro\/con debate","volume":"14","author":"Hobbs","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.kint.2017.12.011_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2017.12.011_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1185\/03007995.2013.779237","article-title":"Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials","volume":"29","author":"Nikolic","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.kint.2017.12.011_bib8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2017.12.011_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2017.12.011_bib10","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2017.12.011_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2017.12.011_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.kint.2017.12.011_bib13","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2017.12.011_bib14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2017.12.011_bib15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials","volume":"223","author":"Farnier","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.kint.2017.12.011_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.kint.2017.12.011_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.12.011_bib18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2017.12.011_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","article-title":"The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia","volume":"134","author":"Haas","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2017.12.011_bib20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","article-title":"PCSK9 in chronic kidney disease","volume":"49","author":"Pavlakou","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.kint.2017.12.011_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.12.011_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/dme.13450","article-title":"Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials","volume":"35","author":"Leiter","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.kint.2017.12.011_bib23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.kint.2017.12.011_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2015.12.007","article-title":"Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention","volume":"205","author":"Konishi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.kint.2017.12.011_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.12.011_bib26","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1194\/jlr.M078212","article-title":"The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab","volume":"58","author":"Enkhmaa","year":"2017","journal-title":"J\u00a0Lipid Res"},{"issue":"suppl 1","key":"10.1016\/j.kint.2017.12.011_bib27","first-page":"4","article-title":"Chronic kidney disease, diabetes mellitus and cardiovascular disease: risks and commonalities","volume":"38","author":"Suckling","year":"2012","journal-title":"J\u00a0Ren Care"},{"key":"10.1016\/j.kint.2017.12.011_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/diaclin.25.3.90","article-title":"Diabetes management issues for patients with chronic kidney disease","volume":"25","author":"Cavanaugh","year":"2007","journal-title":"Clin Diabet"},{"key":"10.1016\/j.kint.2017.12.011_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2017.12.011_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.12.011_bib31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2017.12.011_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/bcp.12905","article-title":"Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms","volume":"81","author":"Sahebkar","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2017.12.011_bib33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2017.12.011_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2017.12.011_bib35","first-page":"299","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2017.12.011_bib36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2017.12.011_bib37","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2017.12.011_bib38","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2017.12.011_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the\u00a0rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2017.12.011_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.kint.2017.12.011_bib41","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818300553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818300553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:50:05Z","timestamp":1758761405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818300553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0085253818300553"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2017.12.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732833174.793544444","asserted-by":"object"}]},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2017.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}